Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Nitride semiconductor laser device
Geographically self-labeling access points
Dual-box location aware and dual-bitmap voltage domain aware on-chip variation techniques
Variety corn line LIC7382
Liquid dispensing apparatus
Method and system for remapping processing elements in a pipeline of a graphics processing unit
Image-monitoring method for electroporation treatment and as associated image-monitoring appliance
  Randomly Featured Patents
Aqueous solution of mixtures of silicon-organic compounds
Explosion proof and watertight enclosure with inspectable means for verifying validity of reclosure
Crystal package for a high-G environment
Electrophotographic photoconductive member and image forming apparatus
Connection of a number of work stations to a single conductor coaxial bus
Optical print head
Federated multiprotocol communication
Network appliance with simplified network transmitter
Transformerless drive circuit for field-effect transistors